-
•
A workhorse technology platform for gene therapy is the
rAAV viral vector system.
-
•
100s of rAAV gene therapy products have entered clinical
development.
-
•
Presently limited by highly complex, expensive, poorly
scalable GMP processes.
-
•
We present the 1st scalable one-component viral vector
system for GMP rAAV manufacturing.
Following purification >80% fully loaded rAAV particles as measured by cryo-EM
